Digital Pharma Europe at Bayer Schering Pharma Headquarters Berlin

29-30 March 2010, Bayer Schering Pharma Headquarters Berlin, Germany.
The time has come for a new kind of event that will help the European Pharmaceutical Industry fully explore and engage in the communications revolution that we are witnessing online. Digital Pharma Europe's mission is to help propel the industry into this new era, and Exl Pharma has assembled an outstanding faculty to lead the event.

Learn about these up to the minute hot topics:

  • Successfully Integrating Digital Media into the Overall Marketing Mix to Serve as an Effective Business Driver
  • Creating successful eRelationships as Foundation for all Web 2.0 Initiatives
  • An Assessment of Currently Available Online Educational Tools for Physicians and How to Make Improvements
  • Social Networks in Health Care: Forgetting What You Know is the First Step in Driving the Most Effective Marketing Campaign
  • Can Pharma Make a Business Case for Social Media? Getting Buy-in For the Web 2.0 Groundswell
  • Web Business Strategies: How To Manage Organizational Aspects
  • and much more...

This conference is designed for European based pharmaceutical, biotechnology, specialty pharma, generic, and medical device companies whose responsibilities include:

  • eMarketing
  • Digital Marketing
  • Relationship Marketing
  • Product/Brand Marketing
  • Physician Marketing
  • eBusiness
  • eDetailing
  • Integrated Solutions
  • Internet Communications
  • Information Technology
  • Legal/Regulatory
  • Compliance Officers

This program is also of interest to:

  • Interactive Agencies
  • Consultants
  • Marketing Service Providers
  • New Media Companies
  • Online Communities
  • Advertising Agencies
  • Legal

For further information and registration, please visit:
http://www.exlpharma.com/events/digital-pharma-europe

About ExL Pharma
ExL Pharma, a division of ExL Events, Inc., is an international leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...